

Sacituzumab govitecan TROPiCS-02

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Delayed deterioration claimed, does not meet ESMO-MCBS QoL standards



Serious and disabling adverse effects



Other adjustments



Sacituzumab govitecan TROPiCS-02

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting

Experimental Arm: Sacituzumab govitecan

Control Arm: Physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)



